(2003; 148 pages)
2.7 Pharmacopoeial Discussion Group (PDG)1
1 Composed of representatives of the European, Japanese and United States pharmacopoeias, with WHO as an observer.
The Committee was informed of the new collaboration between the Pharmacopoeial Discussion Group (PDG) and WHO. The collaboration between WHO and PDG was very well received and was seen as providing a new platform for discussion and communication between pharmacopoeias.
The Committee adopted the following recommendations on WHO collaboration with the PDG made during a consultation held in Geneva in September 2001:
• The joint development of monographs using this forum should be encouraged so as to make the pharmacopoeial requirements for specific priority diseases such as HIV/AIDS, malaria and tuberculosis, available more quickly.
• Existing harmonized monographs, e.g. for excipients, should be included in The International Pharmacopoeia and WHO should contact the PDG for the “modus operandi”.